![Molecular Partners AG logo](/logos/MOLN.SW.webp)
Molecular Partners AG
SIX:MOLN.SW
Overview | Financials
Company Name | Molecular Partners AG |
Symbol | MOLN.SW |
Currency | CHF |
Price | 5.6 |
Market Cap | 185,822,560 |
Dividend Yield | 0% |
52-week-range | 3.04 - 9.5 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Patrick Amstutz Ph.D. |
Website | https://www.molecularpartners.com |
An error occurred while fetching data.
About Molecular Partners AG
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD